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Abstract
Hypophosphatasia (HPP) is a systemic skeletal disease caused by mutations in the gene encoding tissue-nonspecific alkaline 
phosphatase (TNALP). We recently reported that survival of HPP model mice can be prolonged using an adeno-associated 
virus (AAV) vector expressing bone-targeted TNALP with deca-aspartate at the C terminus (TNALP-D10); however, abnor-
mal bone structure and hypomineralization remained in the treated mice. Here, to develop a more effective and clinically 
applicable approach, we assessed whether transfection with TNALP-D10 expressing virus vector at a higher dose than previ-
ously used would ameliorate bone structure defects. We constructed a self-complementary AAV8 vector expressing TNALP 
driven by the chicken beta-actin (CBA) promoter (scAAV8-CB-TNALP-D10). The vector was injected into both quadriceps 
femoris muscles of newborn HPP mice at a dose of 4.5 × 1012 vector genome (v.g.)/body, resulting in 20 U/mL of serum ALP 
activity. The 4.5 × 1012 v.g./body-treated HPP mice grew normally and displayed improved bone structure at the knee joints 
in X-ray images. Micro-CT analysis showed normal trabecular bone structure and mineralization. The mechanical proper-
ties of the femur were also recovered. Histological analysis of the femurs demonstrated that ALP replacement levels were 
sufficient to promote normal, growth plate cartilage arrangement. These results suggest that AAV vector-mediated high-dose 
TNALP-D10 therapy is a promising option for improving the quality of life (QOL) of patients with the infantile form of HPP.
Keywords Hypophosphatasia · Adeno-associated virus vector · Enzyme replacement therapy · Alkaline phosphatase · Bone 
structure
Abbreviations
AAV  Adeno-associated virus
ALP  Alkaline phosphatase
CBA  Chicken beta-actin
EGFP  Enhanced green fluorescence proteinElectronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0022 3-020-00676 -5) contains 
supplementary material, which is available to authorized users.
 * Aki Nakamura-Takahashi 
 atakahashi@tdc.ac.jp
 * Masataka Kasahara 
 mkasahar@tdc.ac.jp
1 Department of Pharmacology, Tokyo Dental College, 
2-9-18, Kandamisaki-cho, Chiyoda-ku, Tokyo 101-0061, 
Japan
2 Tokyo Dental College Research Branding Project, Tokyo 
Dental College, Tokyo, Japan
3 Department of Pediatric Dentistry, Tokyo Dental College, 
Tokyo, Japan
4 Department of Anatomy, Tokyo Dental College, Tokyo, 
Japan
5 Department of Molecular Therapy, National Center 
of Neurology and Psychiatry, National Institute 
of Neuroscience, Tokyo, Japan
6 Division of Clinical Genetics, Kanazawa University Hospital, 
Ishikawa, Japan
7 Division of Molecular and Medical Genetics, The Institute 
of Medical Science, University of Tokyo, Tokyo, Japan
8 Oral Health Science Center, Tokyo Dental College, Tokyo, 
Japan
 A. Nakamura-Takahashi et al.
1 3
ERT  Enzyme replacement therapy
FEA  Finite element analysis
GPI  Glycosylphosphatidylinositol
HPP  Hypophosphatasia
PCR  Polymerase chain reaction
QOL  Quality of life
ROI  Region of interest
TNALP  Tissue-nonspecific alkaline phosphatase
TNALP-D10  Bone-targeted tissue-nonspecific alkaline 
phosphatase with deca-aspartate at the C 
terminus
Introduction
Hypophosphatasia (HPP) is a rare congenital disease caused 
by mutations in the gene encoding tissue-nonspecific alka-
line phosphatase (TNALP) [1, 2]. HPP is characterized by 
defective calcification of hard tissue, pathologic fracture, 
dyspnea, seizures, and premature tooth loss [3, 4]. It is clas-
sified into six different types according to the age at onset 
and symptoms: perinatal severe HPP, perinatal benign HPP, 
infantile HPP, childhood HPP, adult HPP, and odonto-HPP 
[5, 6], with perinatal severe HPP and childhood HPP fre-
quently being fatal [7, 8]. However, treatment for HPP has 
not been well established.
Whyte et al. first applied enzyme replacement therapy 
(ERT) by infusion of alkaline phosphatase (ALP)-rich 
plasma to an infantile patient with HPP [9]. In 2008, Millán 
et al. developed a novel ERT using bioengineered TNALP. 
The novel construct was formed by detaching the glyco-
sylphosphatidylinositol (GPI) anchor from TNALP to allow 
secretion and adding a deca-aspartate motif to the C ter-
minus (TNALP-D10) to increase affinity for bone [10]; the 
latter was possible because TNALP is an ectoenzyme whose 
C terminus is anchored to the cell surface by a GPI anchor 
glycoprotein composed of approximately 500 amino acid 
residues [11]. This method clearly improved the phenotype 
of TNALP-deficient mice [10]. Furthermore, this method 
was applied to patients with HPP and was effective in pro-
longing life span [12, 13]. In 2015, therapy with TNALP-D10 
was approved for the treatment of HPP in Canada, Europe, 
Japan, and the USA. Although this therapy is effective in 
extending life and enabling patients to be weaned from artifi-
cial ventilation [14, 15], further improvements are necessary 
to address the following issues: (1) the HPP patient needs 
to receive repeated subcutaneous injections three times a 
week due to the short half-life of the enzyme [12], (2) the 
replacement enzyme dose must be increased as the patient 
grows, and (3) they have to continue treatment for life [16].
To resolve these problems, several approaches have 
been taken to establish a gene-based therapy to replace 
the enzyme. We have explored this approach using various 
viral vectors in Akp2−/− (TNALP-knockout) HPP model 
mice, as they exhibit dyspnea, seizures, growth failure, and 
bone hypoplasia, resulting in death within 3 weeks of birth 
[17]. Recently, Nakano et al. showed that gene correction 
of induced pluripotent stem cells (iPS cells) isolated from 
two HPP patients rescued ALP activity and mineralization 
in vitro [18], suggesting a possible application of gene-
corrected iPS cells for patients with HPP. These in vivo 
and in vitro experimental systems provide opportunities to 
develop a new therapy that complement the disadvantages 
of ERT.
Our previous studies demonstrated that a single injection 
of adeno-associated virus (AAV) vector, which is not patho-
genic to humans and is very safe, expressing TNALP-D10 in 
an Akp2−/− HPP model mice successfully extended survival 
and corrected skeletal phenotype [19, 20]. However, sev-
eral insufficient therapeutic effects were observed in skeletal 
tissues including hypomineralization of bone and cartilage, 
irregularly arranged trabeculae, partial cortical bone defects, 
and abnormal chondrocyte layer proliferation [20]. Although 
these problems are not directly life-threatening, improved 
treatment methods are required to prevent severely dimin-
ished physical activity.
We conjectured the non-completeness of therapeutic 
effects observed in the previous study [20] might be caused 
by insufficient local replacement of ALP in the bone and 
cartilage. In this study, to validate our assumption, we deter-
mined the optimal AAV vector dose for increasing the local 
ALP concentration in bone and mitigating femoral elonga-
tion, morphological irregularity and hypomineralization. 
Furthermore, we investigated the efficacy of this dose in 
terms of mechanical properties of the femur and spontaneous 
locomotor activity.
Methods
Plasmid Construction and AAV Vector Production
The recombinant self-complementary AAV (scAAV) vec-
tor plasmid, pscAAV-CB-EGFP, was provided by Dr. Arun 
Srivastava of the University of Florida College of Medicine 
(Gainesville, FL, USA). The plasmid pscAAV-CB-TNALP-
D10 was constructed by replacing the enhanced green fluo-
rescence protein (EGFP) region of pscAAV-CB-EGFP with 
the AgeI–HindIII fragment (TNALP-D10 gene) of pAAV-
CAGS-TNALP-D10 using an In-Fusion HD Cloning Kit 
(Clontech Laboratories, TaKaRa Bio Company, Ohtsu, 
Shiga, Japan). Recombinant scAAV8-CB-TNALP-D10 was 
generated using polyethylenimine-based adenovirus-free 
triple transfections of HEK293 cells in serum-free medium 
[21]. The AAV vector titer was determined using real-
time polymerase chain reaction (PCR) using a 7500 Fast 
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Real-Time PCR Instrument (Applied Biosystems, Carlsbad, 
CA) with the following primers for the TNALP-D10 gene: 
forward, 5′-CCG TGG CAA CTC TAT CTT T-3′ and reverse, 
5′-GAG ACA TTC TCT CGT TCA CC-3′.
Animal Procedures and Vector Injection
TNALP-knockout Akp2−/− mice and Akp2+/+ mice were 
obtained by mating Akp2+/− mice with mice with a mixed 
genetic background of 129/J and C57BL/6 J, which were 
generated in the Millán laboratory (La Jolla, CA) [17]. All 
mice were fed ad libitum a rodent diet supplemented with 
325 ppm pyridoxine (vitamin B6)/10 kg of feed (Oriental 
Yeast Co., Ltd., Tokyo, Japan) to suppress seizures [22]. 
Genotyping was performed using PCR with the follow-
ing primers immediately after birth: forward, 5′-AGT CCG 
TGG GCA TTG TGA CTA-3′; and reverse, 5′-TGC TGC TCC 
ACT CAC GTC GAT-3′. To characterize the expression of 
TNALP-D10, scAAV8-CB-TNALP-D10 was injected into 
both quadriceps femoris muscles of neonatal Akp2−/− mice 
on day 1 after birth. The amount of vector injected was 
1.5 × 1011 (n = 8), 7.5 × 1011 (n = 7), 1.5 × 1012 (n = 7), or 
4.5 × 1012 (n = 7) vector genomes (v.g.)/body diluted with 
phosphate-buffered salts (PBS) to a total volume of 20 µL. 
The physical appearance of the mice was observed regularly, 
and body weight was measured every 10 days for 90 days. 
To examine the therapeutic effects of scAAV8-CB-TNALP-
D10, the treated Akp2−/− mice were sacrificed at 90 days of 
age and perfused with 15 mL of PBS. Tissue samples were 
taken from the heart, liver, lung, spleen, kidney, quadriceps 
femoris muscle, genitalia, bone (both hind limbs), and brain. 
Akp2+/+ mice of the same age were used as controls (n = 7).
ALP Activity in Serum
Blood samples were collected from the tail vein or inferior 
vena cava using a 29-gauge insulin syringe on days 30, 60, 
and 90 after birth (n = 7). ALP activity in the serum was 
measured using a colorimetric assay, as described previously 
[23], with 1 U being the amount of enzyme needed to cata-
lyze the generation of 1 µmol p-nitrophenol per min.
X‑ray Analysis
All the radiographic images were recorded on µFX-1000 
film (Fujifilm, Tokyo, Japan). Imaging conditions were as 
follows: tube voltage, 25 kV; tube current, 100 µA; exposure 
time, 30 s [20]. At 90 days after birth, hind limbs were X-ray 
irradiated and imaged with a Typhoon FLA-7000 scanner 
(Fujifilm) (n = 7).
Micro‑computed Tomography Imaging
Micro-computed tomography (micro-CT) analysis was per-
formed using an TDM-1000 scanner (Yamato Scientific, 
Tokyo, Japan). Imaging conditions were as follows: matrix 
size, 1024 × 1024; tube voltage, 60 kV; tube current, 60 µA; 
magnification, × 3.5; filter, 0.1 mm brass; slice pitch, 17 µm; 
voxel size, 17 × 17 × 17 (µm). The growth plate and midshaft 
were selected as the scan site (midshaft = half of the entire 
length) [24] (n = 5).
Morphometric Evaluation of Trabecular Bone
To analyze femur morphometry, we employed the 3D ana-
lytical software TRI/3D-BON (Ratoc System Engineering, 
Tokyo, Japan). The region of interest (ROI) was 1-mm-thick 
and positioned 0.5 mm above the growth plate. Bone mineral 
density, bone volume/tissue volume, trabecular number, tra-
becular thickness, trabecular separation, and marrow space 
star volume were semi-automatically determined in accord-
ance with the guidelines for evaluation of bone microstruc-
ture using 3D images [24, 25].
Histological Analysis
Prepared knee joints were fixed in 4% paraformaldehyde in 
PBS and embedded in Super Cryoembedding Medium com-
pound (Leica Microsystems, Wetzlar, Germany). Then, they 
were frozen without decalcification. Sections 10-µm-thick 
were prepared by the Kawamoto method [26] using Cryo-
film Type IIC (9) (Leica Microsystems, Wetzlar, Germany), 
air-dried for 10 min, washed with PBS, and further washed 
with distilled water. To examine cartilage structure, sec-
tions were stained with Alcian blue solution pH 2.5 (Muto 
Pure Chemicals, Tokyo, Japan) for 30 min, washed with 
distilled water for 2 min, and counterstained with Kernech-
trot (nuclear fast red) stain solution (Muto Pure Chemicals) 
for 1 min. Standard hematoxylin and eosin (H&E) staining 
was performed for histological observation. To analyze ALP 
replenishment areas, sections were stained using an ALP-
staining kit (Muto Pure Chemicals) for 120 min at 37 °C. 
Sections were mounted on MAS-coated glass slides (Mat-
sunami Glass, Tokyo, Japan) and examined under a light 
microscope (n = 5).
Finite Element Analysis
The reconstructed 3D-images obtained using micro-CT were 
exploited for finite element analysis (FEA). The ROI was 
set with the anterior–posterior axis as the X-axis, the inter-
nal–external axis as the Y-axis, and the major axis as the 
Z-axis. It was defined as a 2-mm-thick region spanning from 
1.8 mm proximal to 0.2 mm distal to the growth plate. Using 
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Carter’s equation [27], the Young’s modulus was set at 22 GPa 
for cortical bone and 6 GPa for trabecular bone, and the Pois-
son ratio was set at 0.30 for both bone types. A strain was 
applied to the entire proximal side of the cortical bone and 
trabecular bone. The element on this surface was restrained 
to 1 voxel. Bone fracture was defined as a minimal principal 
strain of 10% or more, and forced displacement was stopped 
when bone fracture reached 2% or more of bone volume [28]. 
Simultaneously, the total reaction force on the bottom sur-
face (= fixed area) was analyzed as a fracture load using the 
TRI/3D-FEM64 FEA software (Ratoc System Engineering, 
Tokyo, Japan) [29] (n = 5).
Spontaneous Locomotor Activity
The spontaneous locomotor activity of mice was measured 
using a dual activity monitor system (Shinfactory, Fukuoka, 
Japan). This system comprised a rectangular enclosure (30 
× 20  cm2) containing a wheel; the side wall of the enclosure 
had infrared sensors at 2-cm intervals [30]. The system was 
placed in a softly illuminated sound-proof room. At 85 days 
after birth, Akp2+/+ mice, and Akp2−/− mice injected with 
AAV vector at 1.5 × 1011 or 4.5 ×  1012 v.g./body, were put in 
the system. After 1 day of training, spontaneous movement 
was recorded for 5 days to determine planar movement (floor 
movement) count number, wheel movement rotational num-
ber, wheel movement total distance, wheel movement average 
speed (average running speed other than 0), wheel movement 
activity time, and wheel movement acceleration (maximum 
running speed); each parameter was calculated per day. The 
spontaneous locomotor activity analyses were carried out 
using a ACTIMO-DATAII software (Bio Research Center, 
Aichi, Japan) (n = 5).
Statistical Analysis
All data are presented as the mean ± SD. Bartlett’s test was 
used to confirm that the data showed a normal distribution and 
similar variance among groups. Differences between multiple 
groups were examined using one-way analysis of variance 
(single-factor ANOVA) and Tukey–Kramer post hoc tests. P 
values less than 0.05 were considered statistically significant. 
Survival rates were estimated using the Kaplan–Meier method, 
and the differences in survival rates were examined using the 
log-rank test. Statistical analyses were conducted in Statcel 4 
for Windows (OMS, Saitama, Japan).
Results
Elevated Serum ALP Activity and Prolonged Survival 
in  Akp2−/− Mice Following Intramuscular Injection 
of scAAV8‑CB‑TNALP‑D10
The vector scAAV8-CB-TNALP-D10 was administered 
intramuscularly to Akp2−/− mice at 1.5 × 1011, 7.5 × 1011, 
1.5 × 1012, or 4.5 × 1012 v.g./body on day 1 after birth. To 
determine ALP levels in the serum, ALP activity was meas-
ured via a colorimetric assay every 30 days after AAV vector 
injection. The serum ALP activity rapidly increased in all 
groups. The effect of the AAV vector was dose dependent: 
Akp2−/− mice treated at 1.5 × 1011, 7.5 × 1011, 1.5 × 1012, or 
4.5 × 1012 v.g./body showed on average 1.69, 1.94, 8.45, and 
24.97 U/mL serum ALP activity, respectively, at day 90 after 
birth (Fig. 1a). High vector copy numbers were observed in 
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Fig. 1  Effect of TNALP-D10 dose on serum ALP activity and sur-
vival rate. Akp2−/− mice were untreated or injected with the indicated 
doses of AAV vector (scAAV8-CB-TNALP-D10) at day 1 after birth. 
Untreated Akp2+/+ mice were used as a control. a Serum ALP activity 
measured at the indicated days after birth. Error bars, SD (n = 7). b 
Kaplan–Meier survival analysis of AAV vector-treated Akp2−/− mice. 
Treatment with AAV vector at all test doses improved the survival 
rate significantly compared with that of untreated mice. ***P < 0.001
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sites) (Fig. S1A). Moreover, ALP activity was very high 
in the quadriceps femoris muscle but low in the liver (Fig. 
S1B). Untreated Akp2−/− mice had a normal appearance but 
experienced epileptic seizures and hypomineralization by 
day 10 after birth and died within 3 weeks of birth. In con-
trast, treated mice displayed significantly prolonged survival 
rates at all vector doses (P < 0.001, log-rank test) (Fig. 1b).
Promotion of Weight Gain and Femur Elongation 
by a High Dose of TNALP‑D10
Body weight and femur length were used to assess the 
growth of AAV vector-transduced mice. Akp2−/− mice 
treated with a high dose (4.5 × 1012 v.g./body) of AAV vec-
tor achieved normal weight gain at day 90 after birth: that 
is, the body weight of the treated mice (24.58 ± 1.89 g) was 
similar to that of the control mice (24.78 ± 2.49 g). However, 
Akp2−/− mice treated with lower doses showed stagnated 
weight gain after day 20 (Fig. 2a); the differences in body 
weight between these groups and the control mice were 
significant at day 90 (> 5 g difference; Fig. 2b). In X-ray 
images taken at day 90, irregular shapes of the knee joint 
were seen in the hind limbs of mice treated with the lowest 
dose (1.5 × 1011 v.g./body) and two middle doses (7.5 × 1011 
v.g./body and 1.5 × 1012 v.g./body) of AAV vector; con-
versely, control mice and mice treated with the highest does 
(4.5 × 1012 v.g./body) exhibited normal knee joint formation 
(Fig. 2c). Femur lengths did not differ significantly between 
mice treated with 4.5 × 1012 v.g./body (14.02 ± 0.43 mm) and 
control mice (14.66 ± 0.38 mm); however, mice treated with 
Fig. 2  Effect of TNALP-D10 
high-dose on growth. Akp2−/− 
mice were untreated or injected 
with the indicated doses of 
AAV vector (scAAV8-CB-
TNALP-D10) at day 1 after 
birth. Untreated Akp2+/+ mice 
were used as a control. a All 
mice were weighed after birth 
and then every 10 days until 
day 90. The growth curve of 
Akp2−/− mice treated with 
4.5 × 1012 v.g./body vector was 
similar to that of the control 
mice. Error bars, SD (male, 
n = 4; female, n = 3). b Weight 
comparison of each group 
at 90 days after birth. Mice 
treated with 4.5 × 1012 v.g./
body showed a similar weight 
gain to that of the control 
mice. Error bars, SD (male, 
n = 4; female, n = 3). *P < 0.05; 
**P < 0.01: NS, not significant. 
c Representative X-ray images 
of the hind limbs of mice 
treated with 4.5 × 1012 v.g./
body, taken at 90 days after 
birth; the bone structure at the 
joint showed normal morphol-
ogy. Whereas irregular shapes 
of the knee joint is seen in the 
hind limbs of mice treated with 
the lower doses (1.5 × 1011 
v.g./body, 7.5 × 1011 v.g./body 
and 1.5 × 1012 v.g./body) of 
AAV vector. White arrows are 
irregular knee shape. Scale bars, 
4 mm. d Femur lengths of mice 
treated with 4.5 × 1012 v.g./
body AAV vector were similar 
to those of control mice. Error 
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lower doses had significantly shorter femurs than control 
mice (> 2 mm difference; all P < 0.01; Fig. 2d).
Restoration of Normal Bone Structure and Bone 
Quality Upon Administration of High Dose 
of TNALP‑D10
We conducted a micro-CT analysis of the femoral structure 
in Akp2−/− mice treated with AAV vector at 1.5 × 1011 v.g./
body or 4.5 × 1012 v.g./body. The images showed irregular 
shape of growth plate, decrease in trabecular bones and 
defect and thinning of cortical bone in the mice treated with 
1.5 × 1011 v.g./body. In contrast, these morphological abnor-
malities were not observed in mice treated with 4.5 × 1012 
v.g./body; these mice exhibited the same bone structure as 
the control mice (Fig. 3a). In trabecular bone analysis of the 
ROI, images indicated that mice exhibited numerous cavi-
ties as a result of the low number of trabeculae and the bone 
Fig. 3  Micro-CT analysis of the 
effect of TNALP-D10 high-dose 
on bone structure. Akp2−/− mice 
were injected with the indicated 
dose of AAV vector (scAAV8-
CB-TNALP-D10) at day 1 
after birth. Untreated Akp2+/+ 
mice were used as a control. 
a Representative micro-CT 
images of femur taken on day 
90 after birth. Femurs of mice 
treated with 4.5 × 1012 v.g./body 
displayed uniform cortical bone, 
and there were no differences in 
epiphyseal cupping compared 
with control mice. However, 
femur of mice treated with 
1.5 × 1012 v.g./body showed 
defects (white arrows) and thin-
ning (yellow arrow) of cortical 
bone. White box indicates 
irregular shape of growth plate. 
Scale bars, 1 mm. b Images 
of regions of interest (ROIs) 
in cancellous bone analysis. 
Trabecular arrangement in the 
ROI of the mice treated with 
4.5 × 1012 v.g./body was similar 
to that in the control mice. Scale 
bars, 1 mm. c Morphometric 
evaluation of trabecular bone. In 
the mice treated with 4.5 × 1012 
v.g./body, all parameters exam-
ined were recovered to the same 
values as those in control mice. 
BMD, bone mineral density; 
BV/TV, bone volume/tissue vol-
ume; Tb.N, trabecular number; 
Tb.Th, trabecular thickness; 
Tb.Sp, trabecular separation; 
V*m. Space, marrow space star 
volume. Error bars, SD (n = 5). 
*P < 0.05; **P < 0.01: NS not 
significant
Entire femur
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width unusually wide in mice treated with 1.5 × 1011 v.g./
body. In marked contrast, the bone structure was normal 
in mice treated with 4.5 × 1012 v.g./body (Fig. 3b). Indeed, 
for all parameters measured in the trabecular bone analysis 
(bone mineral density, bone volume/tissue volume, trabecu-
lar number, trabecular thickness, trabecular separation, and 
marrow space star volume), the values in mice treated with 
1.5 × 1011 v.g./body were significantly lower than those in 
control mice and there was no significant difference between 
mice treated with 4.5 × 1012 v.g./body and control mice 
(Fig. 3c).
Normal Skeletal Structure in Histological Analysis 
Following a High Dose of TNALP‑D10
To observe the condition of cartilaginous tissue, the growth 
plate and epiphysis of the femurs of treated mice were sub-
jected to Alcian blue staining and Kernechtrot counterstain-
ing. In Akp2−/− mice treated with 1.5 × 1011 v.g./body, the 
growth plate cartilage was structurally disrupted and abnor-
mally arranged, and the articular cartilage in the epiphysis 
was abnormally thick. In contrast, the arrangement of the 
growth plate cartilage and the thickness of articular cartilage 
in the epiphysis in Akp2−/− mice treated with 4.5 × 1012 v.g./
body was similar to that in control mice (Fig. 4a). Ectopic 
fibrous tissue was observed in H&E staining images of the 
epiphysis and cortical bone in mice treated with 1.5 × 1011 
v.g./body, but not in those treated with 4.5 × 1012 v.g./body 
or in control mice (Fig. 4b).
We performed ALP staining of the growth plate, epi-
physis, and cortical bone in the femurs of Akp2−/− mice 
treated with 1.5 × 1011 or 4.5 × 1012 v.g./body. The ALP 
distribution in mice treated with 4.5 × 1012 v.g./body was 
similar to that in control mice: i.e., ALP was distributed 
in the hypertrophic chondrocyte layer of the growth plate, 
the surface of glenoid trabecular bone, and the periosteum. 
However, only a few weak spots of ALP were observed in 
mice treated with 1.5 × 1011 v.g./body (Fig. 4c). Ectopic 
structures were not observed in control mice but were 
observed in the knee joint or cortical bone near the knee 
joint in mice treated with 1.5 × 1011 or 4.5 × 1012 v.g./body. 
The properties of ectopic structures differed between mice 
treated with 1.5 × 1011 and those treated with 4.5 × 1012 
v.g./body, as outlined below. The ectopic structures in 





















Alcian blue staining H&E staining ALP stainingKnee joint
Fig. 4  Histological examination of the effect of TNALP-D10 high-
dose on bone structure. Akp2−/− mice were injected with the indicated 
doses of AAV8 vector (scAAV8-CB-TNALP-D10) at day 1 after birth. 
Untreated Akp2+/+ mice were used as a control (n = 5). a Alcian blue 
and Kernechtrot (nuclear fast red) staining of femur, growth plate, 
and epiphysis at 90  days after birth. The growth plate chondrocyte 
layer of mice treated with 4.5 × 1012 v.g./body was regularly arranged, 
whereas mice treated with 1.5 × 1011 v.g./body was irregular 
arranged. Scale bars: femur, 500 µm; growth plate, 200 µm; glenoid 
fossa, 200 µm. b Hematoxylin and eosin staining. Black arrows indi-
cate ectopic fibrous tissue. Abnormal fibrous tissue was not observed 
in mice treated with AAV vector at 4.5 × 1012 v.g./body. Scale bars: 
femur, 500  µm; glenoid fossa, 200  µm; and cortical bone, 200  µm. 
c ALP staining. Black arrows indicate weak positive spots for ALP. 
In mice treated at 4.5 × 1012 v.g./body, the levels of serum ALP were 
sufficient for ALP to be distributed locally in the bone. Scale bars: 
femur, 500  µm; growth plate, 200  µm; glenoid fossa, 200  µm; cor-
tical bone, 200  µm. d Ectopic structure images. Ectopic structures 
were detected in both mice treated with 1.5 × 1011 v.g./body and those 
treated with 4.5 × 1012 v.g./body. Black arrows indicate ectopic struc-
ture. Scale bars, 200 µm
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chondrocytes; ALP staining was negative and mineraliza-
tion was not observed. In contrast, the ectopic structures in 
mice treated with 4.5 × 1012 were ectopic bones, in which 
the trabecular bone construction and detected surface of 
trabecular bone were ALP positive (Fig. 4d).
Ability of Femoral Strength to Withstand 
Normal Mechanical Stress Following High Doses 
of TNALP‑D10
We performed FEA of the femur epiphysis in Akp2−/− mice 
treated with 1.5 × 1011 or 4.5 × 1012 v.g./body; the ROI 
and analytical conditions are shown in Fig. 5a. The bone 
strength (fracture load) of mice treated with 1.5 × 1011 v.g./
body was significantly lower than that of control mice. In 
contrast, the bone strength of mice treated with 4.5 × 1012 
v.g./body mice did not differ significantly from that of con-
trol mice (Fig. 5b).
Failure to Restore Normal Spontaneous Locomotor 
Activity with a High Dose of TNALP‑D10
Using a wheel cage, we investigated the spontaneous loco-
motor activity of Akp2−/− mice treated with AAV vector at 
1.5 × 1011 or 4.5 × 1012 v.g./body (Fig. 6). The present study 
is the first to include a long-term analysis of spontaneous 
activity. There was no significant difference in the planar 
movement count number between the AAV-treated mice and 
the control mice. However, wheel movement was signifi-
cantly lower in terms of rotation number, total distance, and 
activity time in both mice treated with 1.5 × 1011 v.g./body 
and those treated with 4.5 × 1012 v.g./body than in control 
mice.
Discussion
In previous studies, we successfully prolonged the survival 
of HPP mice by TNALP-D10 replacement via the single 
administration of lentivirus vector [31] or an AAV vector 
[19, 20]. However, detailed analysis of the femurs of these 
mice revealed issues, including morphological irregularity, 
insufficient extension, and hypomineralization, suggesting 
that the condition was not fully resolved and that the AAV 
vector dosage may have been suboptimal [20]. Consider-
ing the application to patients with HPP, these results sug-
gested that suboptimal dose would not prevent patients from 
suffering from growth impairment leading to short stature 
and persistent susceptibility to fractures. Because the most 
severe type of HPP affects infants and young children at 
an age when they are growing rapidly, growth impairment 
causing short stature is psychologically distressing for both 
patients and their families, and persistent susceptibility to 
fractures leads to skeletal deformity and ultimately contrib-
utes to impaired physical function. Accordingly, although 
these problems are not life-threatening, they severely dimin-
ish the QOL of patients and their families [32–34]. Such 
impaired growth has already been observed in patients with 
HPP receiving the current enzyme replacement therapy, 
with data showing that their height and weight are greater 
than two standard deviations below the mean [14]. There is, 
therefore, a need to develop new treatment regimens capable 
of ameliorating the insufficient elongation, morphological 
irregularity, and hypomineralization of the femur by com-
paring the effects of ERT.
In this study, to investigate the optimum AAV vector 
dose needed to ameliorate femoral morphological irregular-
ity and hypomineralization, we administered four different 
doses of scAAV8-CB-TNALP-D10 (1.5 × 1011, 7.5 × 1011, 
1.5 × 1012, or 4.5 × 1012 v.g./body) by intramuscular injec-
tion into both quadriceps femoris muscles of HPP mice. 
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Fig. 5  FEA assessment of the effect of TNALP-D10 high-dose on 
femoral strength. Akp2−/− mice were injected with the indicated 
doses of AAV vector (scAAV8-CB-TNALP-D10) at day 1 after birth. 
Untreated Akp2+/+ mice were used as a control (n = 5). a Schematic 
of a region of interest (ROI) and analytical conditions. X-axis, ante-
rior–posterior axis; Y-axis, internal–external axis; Z-axis, major 
axis. b Fracture load was determined by FEA at 90 days after birth. 
The femurs of mice treated with 4.5 × 1012 v.g./body could tolerate 
mechanical stress to a similar level as those of control mice. Error 
bars, SD. *P < 0.05; **P < 0.01: NS not significant
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mL, thereby prolonging survival of the mice. This result 
is consistent with previous reports [19, 20]. We observed 
high vector copy numbers in liver and injected muscle, and 
high-ALP activity in muscle. It is known from clinical trials 
in hemophilia B patients that transduction does not result in 
long-term sustained gene expression in the liver because of 
the immune reaction to the viral capsid [35]. On the basis 
of this observation, we assume that, although transduction 
of AAV vector is easily achieved in muscle and liver [21], it 
does not persist in the liver.
Normal body weight and femoral length were achieved 
only in HPP mice that received a dose of 4.5 × 1012 v.g./
body; those that received lower doses exhibited plateaus in 
weight gain and impaired femoral elongation. In previous 
discussions on enzyme replacement therapy in HPP mice, 
it has been argued that the lack of adipose tissue in treated 
mice results in a plateauing of weight gain that must be due 
to a mechanism other than morphological irregularities of 
bone [36]. However, data from this study showed that, like 
the control mice, HPP mice treated with 4.5 × 1012 v.g./
body had normal-length femurs, and their weight gain did 
not plateau but continued to increase until they ultimately 
reached normal weight. These results suggest that persistent 
insufficient bone elongation is likely a direct cause of the 
plateau in weight gain. We performed a micro-CT analysis to 
observe the femoral morphology in greater detail. HPP mice 
treated with 1.5 × 1011 v.g./body, which resulted in a serum 
ALP activity of 1 U/mL and was found to extend survival, 
exhibited morphological irregularities, including persistent 
epiphyseal cupping, irregularly arranged trabeculae, cortical 
bone defects, and non-uniform cortical bone thickness in 
previous studies [20]. Cancellous bone analysis confirmed 
that the disease also remained unresolved in quantitative 
terms. In contrast, HPP mice treated with 4.5 × 1012 v.g./
body exhibited bone morphology that was almost identi-
cal to that of the control mice, and the values measured in 
the cancellous bone analysis and FEA also improved. These 
findings support the hypothesis that the level of serum ALP 
activity required to prolong survival (1 U/mL) is insuffi-
cient in terms of local ALP replacement in femoral bone. 
Fig. 6  Effect of TNALP-D10 
dose on spontaneous movement. 
Akp2−/− mice were injected 
with the indicated doses of 
AAV8 vector (scAAV8-CB-
TNALP-D10) at day 1 after 
birth. Untreated Akp2+/+ mice 
were used as a control. In terms 
of wheel movement rotation 
number (/day) and wheel move-
ment total distance (m/day), 
spontaneous movement was sig-
nificantly lower in mice treated 
with both 1.5 × 1011 v.g./body 
and 4.5 × 1012 v.g./body than in 
the control mice. Error bars, SD 
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At this serum ALP level, the disease remains unresolved in 
a number of aspects, including insufficient elongation of the 
femur, epiphyseal cupping, irregularly arranged trabeculae, 
hypomineralization, and cortical bone defects. It also sug-
gests that administering TNALP-D10 at a sufficiently high 
dose for local femoral bone may ameliorate these unresolved 
problems.
To evaluate the histological condition of bone, we con-
ducted Alcian blue staining, H&E staining, and ALP stain-
ing. In HPP mice treated with 1.5 × 1011 v.g./body, histo-
logical staining revealed morphological irregularities in 
the growth plate cartilage and articular cartilage as well as 
ectopic fibrous tissue in the epiphysis and cortical bone, 
and there were only a few weak positive spots in the ALP 
staining. In contrast, mice treated with 4.5 × 1012 v.g./body 
exhibited the same morphology and ALP distribution as 
those seen in the control group. This result lends further 
support to the hypothesis that TNALP-D10 replacement at a 
dose sufficient to achieve normal levels of ALP in local bone 
brings about normal calcareous degeneration of the hyper-
trophic chondrocyte layer, leading to normal endochondral 
ossification [37], and ameliorates insufficient elongation, 
morphological irregularity, and hypomineralization of the 
femur. In the present study, we applied the frozen sections 
(10 µm thick) obtained from unfixed and undecalcified bone 
tissues to detect more accurate ALP activity. This technique 
provided successful detection of ALP activity, but it failed 
to observe details of chondrocyte columnar arrangement 
due to the reduced resolution of histology. Application of 
more advanced technique to detect accurate ALP activity 
retaining detailed morphology will be necessary to compare 
accurate therapeutic effects between ERT and gene therapy 
at histological level.
In the bone strength analysis of the epiphyseal ROI in 
HPP mice treated with 1.5 × 1011 v.g./body, we found that 
the growth plate and trabeculae were unable to absorb the 
mechanical stress generated by forced displacement and 
exhibited extremely fragile structural characteristics com-
pared with those of control mice. In contrast, in HPP mice 
treated with 4.5 × 1012 v.g./body, which had bone morphol-
ogy almost identical to that of the control group, these areas 
were able to withstand displacement to a level comparable 
to that of the control group. This finding suggests that the 
persistence of cortical bone defects, reduced trabecular num-
bers, and irregularly arranged trabeculae observed in HPP 
mice treated with suboptimal doses of vector may interfere 
with one of the most important functions of bone—its role as 
a supporting tissue maintaining the body’s structure against 
its own weight.
Although femoral morphology was improved in HPP 
mice treated with 4.5 × 1012 v.g./body, histological analy-
sis unexpectedly revealed the presence of ectopic bone 
structures in these mice, which will be an adverse effect 
of the treatment. We speculate that these structures relate 
to the timing of the start of treatment. Because treatment 
began neonatally, endochondral ossification in utero went 
untreated, and hypertrophic chondrocytes did not undergo 
calcareous degeneration, and overproliferated. As a result, 
overproliferated cartilages of the epiphysis may have sepa-
rated when force was applied. The ectopic calcification seen 
in the HPP mice treated with 4.5 × 1012 v.g./body may have 
been formed by TNALP-D10 replacement in this detached 
cartilage. This issue might be resolved by starting the treat-
ment in utero, and we are now planning to conduct fetal gene 
therapy experiments. Here, we found that a high dose of 
4.5 × 1012 v.g./body was required to provide sufficient ALP 
replacement in local bone to ameliorate the signs of HPP. In 
gene therapy using large animals, intravenous administration 
of high doses of AAV vectors reportedly causes liver toxicity 
[38, 39]. This toxicity is likely caused not only by the pres-
ence of contaminating proteins or the method of viral vector 
preparation [40, 41] but also by the viral load or promotor 
sequence [39]. Previous studies have found that the treat-
ment vector is more easily introduced into bone when gene 
therapy is conducted in utero rather than neonatally [42]. 
Investigating in utero gene therapy could enable a lower dose 
of the vector to be administered, which is desirable from a 
safety perspective.
The symptoms of HPP patients include muscle weak-
ness and muscle pain, and many patients exhibit delayed or 
impaired motor development [43, 44]. Here, although there 
was no significant difference in activity levels on the floor 
between the control mice and HPP mice treated with AAV 
vector at 1.5 × 1011 or 4.5 × 1012 v.g./body, we found that the 
activity in the wheel cage was lower in HPP mice at all treat-
ment doses examined than in control mice. We previously 
reported that activity was restored in the treated HPP mice 
[20]; however, in that study, we performed only a short-
term analysis of activity levels on the floor. Our investiga-
tion of daily spontaneous activity in a wheel cage provided 
the important knowledge that the activity level does not, in 
fact, recover, even in mice treated with 4.5 × 1012 v.g./body. 
Given our finding that the structure and strength of bone 
did recover in these mice, we considered that joint or mus-
cle abnormalities may be present. Attempts have recently 
been made to create large-animal models of HPP, and the 
successful establishment of an ovine HPP model using 
CRISPR/Cas9 has been reported [45]. At 2 months of age, 
the HPP model sheep showed signs of muscle weakness, 
with a qualitatively altered gait, and skeletal muscle biopsy 
revealed abnormalities in muscle fiber size and incorrectly 
folded mitochondrial cristae [45]. Myopathy has also been 
reported in HPP patients, with muscle biopsy revealing no 
abnormalities in some cases [46] but abnormalities in mus-
cle fiber size in others [43]. This mechanism is currently 
under investigation.
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Conclusion
In this study, injection of model HPP mice with scAAV8-
CB-TNALP-D10 at an optimal high dose resulted in high 
levels of bone ALP activity and induced normal growth and 
improved bone formation. Therefore, optimized AAV vec-
tor-mediated TNALP-D10 replacement therapy is a promis-
ing option for improvement of the QOL of patients with the 
infantile form of HPP. Further studies concerning the com-
parison of the therapeutic effect between our gene therapy 
and ERT are necessary using Akp2−/− mice before clinical 
application.
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